<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39329897</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4468</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>23</Day></PubDate></JournalIssue><Title>Antibodies (Basel, Switzerland)</Title><ISOAbbreviation>Antibodies (Basel)</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 Infection Enhances Humoral Immune Response in Vaccinated Liver Transplant Recipients.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">78</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/antib13030078</ELocationID><Abstract><AbstractText>In the spring of 2020, the SARS-CoV-2 pandemic presented a formidable challenge to national and global healthcare systems. Immunocompromised individuals or those with relevant pre-existing conditions were particularly at risk of severe coronavirus disease 2019 (COVID-19). Thus, understanding the immunological processes in these patient groups is crucial for current research. This study aimed to investigate humoral immunity following vaccination and infection in liver transplant recipients. Humoral immunity analysis involved measuring IgG against the SARS-CoV-2 spike protein (anti-S IgG) and employing a surrogate virus neutralization test (sVNT) for assessing the hACE2 receptor-binding inhibitory capacity of antibodies. The study revealed that humoral immunity post-vaccination is well established, with positive results for anti-S IgG in 92.9% of the total study cohort. Vaccinated and SARS-CoV-2-infected patients exhibited significantly higher anti-S IgG levels compared to vaccinated, non-infected patients (18,590 AU/mL vs. 2320 AU/mL, <i>p</i> &lt; 0.001). Additionally, a significantly elevated receptor-binding inhibitory capacity was observed in the <i>cPass<sup>TM</sup>TM</i> sVNT (96.4% vs. 91.8%, <i>p</i> = 0.004). Furthermore, a substantial enhancement of anti-S IgG levels (<i>p</i> = 0.034) and receptor-binding inhibition capacity (<i>p</i> &lt; 0.001) was observed with an increasing interval post-transplantation (up to 30 years), calculated by generalized linear model analysis. In summary, fully vaccinated liver transplant recipients exhibit robust humoral immunity against SARS-CoV-2, which significantly intensifies following infection and with increasing time after transplantation. These findings should be considered for booster vaccination schemes for liver transplant recipients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Adiprasito</LastName><ForeName>Jan Basri</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Münster, 48149 Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nowacki</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-4530-5786</Identifier><AffiliationInfo><Affiliation>Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Münster, 48149 Muenster, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine and Gastroenterology, Marienhospital Steinfurt, 48565 Steinfurt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vollenberg</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Münster, 48149 Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meier</LastName><ForeName>Jörn Arne</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Münster, 48149 Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rennebaum</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Münster, 48149 Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schomacher</LastName><ForeName>Tina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Münster, 48149 Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trebicka</LastName><ForeName>Jonel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Münster, 48149 Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Julia</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-6138-7454</Identifier><AffiliationInfo><Affiliation>Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Münster, 48149 Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorentzen</LastName><ForeName>Eva U</ForeName><Initials>EU</Initials><Identifier Source="ORCID">0000-0002-5570-1897</Identifier><AffiliationInfo><Affiliation>Institute of Virology, University Hospital Muenster, 48149 Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tepasse</LastName><ForeName>Phil-Robin</ForeName><Initials>PR</Initials><Identifier Source="ORCID">0000-0002-2757-4755</Identifier><AffiliationInfo><Affiliation>Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Münster, 48149 Muenster, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Antibodies (Basel)</MedlineTA><NlmUniqueID>101587489</NlmUniqueID><ISSNLinking>2073-4468</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2 infection</Keyword><Keyword MajorTopicYN="N">humoral immunity</Keyword><Keyword MajorTopicYN="N">liver transplantation</Keyword><Keyword MajorTopicYN="N">surrogate virus neutralization test</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>16</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>9</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39329897</ArticleId><ArticleId IdType="pmc">PMC11428549</ArticleId><ArticleId IdType="doi">10.3390/antib13030078</ArticleId><ArticleId IdType="pii">antib13030078</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wu J.T., Leung K., Leung G.M. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: A modelling study. Lancet. 2020;395:689–697. doi: 10.1016/S0140-6736(20)30260-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30260-9</ArticleId><ArticleId IdType="pmc">PMC7159271</ArticleId><ArticleId IdType="pubmed">32014114</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z., McGoogan J.M. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–1242. doi: 10.1001/jama.2020.2648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.2648</ArticleId><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Imam A., Abukhalaf S.A., Merhav H., Abu-Gazala S., Cohen-Arazi O., Pikarsky A.J., Safadi R., Khalaileh A. Prognosis and Treatment of Liver Transplant Recipients in the COVID-19 Era: A Literature Review. Ann. Transplant. 2020;25:e926196. doi: 10.12659/AOT.926196.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/AOT.926196</ArticleId><ArticleId IdType="pmc">PMC7602367</ArticleId><ArticleId IdType="pubmed">33106469</ArticleId></ArticleIdList></Reference><Reference><Citation>Thuluvath P.J., Robarts P., Chauhan M. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases. J. Hepatol. 2021;75:1434–1439. doi: 10.1016/j.jhep.2021.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2021.08.008</ArticleId><ArticleId IdType="pmc">PMC8387568</ArticleId><ArticleId IdType="pubmed">34454993</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruether D.F., Schaub G.M., Duengelhoef P.M., Haag F., Brehm T.T., Fathi A., Wehmeyer M., Jahnke-Triankowski J., Mayer L., Hoffmann A., et al. SARS-CoV2-specific Humoral and T-cell Immune Response After Second Vaccination in Liver Cirrhosis and Transplant Patients. Clin. Gastroenterol. Hepatol. 2022;20:162–172.e9. doi: 10.1016/j.cgh.2021.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2021.09.003</ArticleId><ArticleId IdType="pmc">PMC8427908</ArticleId><ArticleId IdType="pubmed">34509643</ArticleId></ArticleIdList></Reference><Reference><Citation>Harberts A., Schaub G.M., Ruether D.F., Duengelhoef P.M., Brehm T.T., Karsten H., Fathi A., Jahnke-Triankowski J., Fischer L., Addo M.M., et al. Humoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant Recipients. Clin. Gastroenterol. Hepatol. 2022;20:2558–2566.e5. doi: 10.1016/j.cgh.2022.06.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2022.06.028</ArticleId><ArticleId IdType="pmc">PMC9287575</ArticleId><ArticleId IdType="pubmed">35850415</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrera S., Colmenero J., Pascal M., Escobedo M., Castel M.A., Sole-González E., Palou E., Egri N., Ruiz P., Mosquera M., et al. Cellular and humoral immune response after mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients. Am. J. Transplant. 2021;21:3971–3979. doi: 10.1111/ajt.16768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.16768</ArticleId><ArticleId IdType="pmc">PMC9800111</ArticleId><ArticleId IdType="pubmed">34291552</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall V., Foulkes S., Insalata F., Kirwan P., Saei A., Atti A., Wellington E., Khawam J., Munro K., Cole M., et al. Protection against SARS-CoV-2 after COVID-19 Vaccination and Previous Infection. N. Engl. J. Med. 2022;386:1207–1220. doi: 10.1056/NEJMoa2118691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118691</ArticleId><ArticleId IdType="pmc">PMC8908850</ArticleId><ArticleId IdType="pubmed">35172051</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobrovitz N., Ware H., Ma X., Li Z., Hosseini R., Cao C., Selemon A., Whelan M., Premji Z., Issa H., et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: A systematic review and meta-regression. Lancet Infect. Dis. 2023;23:556–567. doi: 10.1016/S1473-3099(22)00801-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00801-5</ArticleId><ArticleId IdType="pmc">PMC10014083</ArticleId><ArticleId IdType="pubmed">36681084</ArticleId></ArticleIdList></Reference><Reference><Citation>Vollenberg R., Tepasse P.-R., Kühn J.E., Hennies M., Strauss M., Rennebaum F., Schomacher T., Boeckel G., Lorentzen E., Bokemeyer A., et al. Humoral Immune Response in IBD Patients Three and Six Months after Vaccination with the SARS-CoV-2 mRNA Vaccines mRNA-1273 and BNT162b2. Biomedicines. 2022;10:171. doi: 10.3390/biomedicines10010171.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10010171</ArticleId><ArticleId IdType="pmc">PMC8774019</ArticleId><ArticleId IdType="pubmed">35052849</ArticleId></ArticleIdList></Reference><Reference><Citation>Vollenberg R., Tepasse P.-R., Lorentzen E., Nowacki T.M. Impaired Humoral Immunity with Concomitant Preserved T Cell Reactivity in IBD Patients on Treatment with Infliximab 6 Month after Vaccination with the SARS-CoV-2 mRNA Vaccine BNT162b2: A Pilot Study. J. Pers. Med. 2022;12:694. doi: 10.3390/jpm12050694.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm12050694</ArticleId><ArticleId IdType="pmc">PMC9146879</ArticleId><ArticleId IdType="pubmed">35629116</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoefbaenker M., Neddermeyer R., Guenther T., Mueller M.M., Romberg M.-L., Classen N., Hennies M.T., Hrincius E.R., Ludwig S., Kuehn J.E., et al. Surrogate Virus Neutralisation Test Based on Nanoluciferase-Tagged Antigens to Quantify Inhibitory Antibodies against SARS-CoV-2 and Characterise Omicron-Specific Reactivity in a Vaccination Cohort. Vaccines. 2023;11:1832. doi: 10.3390/vaccines11121832.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11121832</ArticleId><ArticleId IdType="pmc">PMC10748151</ArticleId><ArticleId IdType="pubmed">38140236</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C.W., Chia W.N., Qin X., Liu P., Chen M.I.-C., Tiu C., Hu Z., Chen V.C.-W., Young B.E., Sia W.R., et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat. Biotechnol. 2020;38:1073–1078. doi: 10.1038/s41587-020-0631-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-020-0631-z</ArticleId><ArticleId IdType="pubmed">32704169</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor S.C., Hurst B., Charlton C.L., Bailey A., Kanji J.N., McCarthy M.K., Morrison T.E., Huey L., Annen K., DomBourian M.G., et al. A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection. J. Clin. Microbiol. 2021;59:e02438-20. doi: 10.1128/JCM.02438-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.02438-20</ArticleId><ArticleId IdType="pmc">PMC8092720</ArticleId><ArticleId IdType="pubmed">33500361</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiolet T., Kherabi Y., MacDonald C.-J., Ghosn J., Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review. Clin. Microbiol. Infect. 2022;28:202–221. doi: 10.1016/j.cmi.2021.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.10.005</ArticleId><ArticleId IdType="pmc">PMC8548286</ArticleId><ArticleId IdType="pubmed">34715347</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas E.J., Angulo F.J., McLaughlin J.M., Anis E., Singer S.R., Khan F., Brooks N., Smaja M., Mircus G., Pan K., et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: An observational study using national surveillance data. Lancet. 2021;397:1819–1829. doi: 10.1016/S0140-6736(21)00947-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00947-8</ArticleId><ArticleId IdType="pmc">PMC8099315</ArticleId><ArticleId IdType="pubmed">33964222</ArticleId></ArticleIdList></Reference><Reference><Citation>Naaber P., Tserel L., Kangro K., Sepp E., Jürjenson V., Adamson A., Haljasmägi L., Rumm A.P., Maruste R., Kärner J., et al. Dynamics of antibody response to BNT162b2 vaccine after six months: A longitudinal prospective study. Lancet Reg. Health Eur. 2021;10:100208. doi: 10.1016/j.lanepe.2021.100208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100208</ArticleId><ArticleId IdType="pmc">PMC8418937</ArticleId><ArticleId IdType="pubmed">34514454</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews N., Stowe J., Kirsebom F., Toffa S., Sachdeva R., Gower C., Ramsay M., Lopez Bernal J. Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England. Nat. Med. 2022;28:831–837. doi: 10.1038/s41591-022-01699-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01699-1</ArticleId><ArticleId IdType="pmc">PMC9018410</ArticleId><ArticleId IdType="pubmed">35045566</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala-Borges B., Escobedo M., Egri N., Herrera S., Crespo M., Mirabet S., Arias-Cabrales C., Vilella A., Palou E., Mosquera M.M., et al. Impact of SARS-CoV-2 Infection on Humoral and Cellular Immunity in a Cohort of Vaccinated Solid Organ Transplant Recipients. Vaccines. 2023;11:1845. doi: 10.3390/vaccines11121845.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11121845</ArticleId><ArticleId IdType="pmc">PMC10747916</ArticleId><ArticleId IdType="pubmed">38140248</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirchner T., Heinrich S., Bonifacius A., Engel B., Ruhl L., Pink I., Thomas N., Martens J., Hoeper M.M., Blasczyk R., et al. Reduced humoral but stable cellular SARS-CoV-2-specific immunity in liver transplant recipients in the first year after COVID-19. PLoS ONE. 2022;17:e0276929. doi: 10.1371/journal.pone.0276929.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0276929</ArticleId><ArticleId IdType="pmc">PMC9629592</ArticleId><ArticleId IdType="pubmed">36322587</ArticleId></ArticleIdList></Reference><Reference><Citation>Caballero-Marcos A., Salcedo M., Alonso-Fernández R., Rodríguez-Perálvarez M., Olmedo M., Graus Morales J., Cuervas-Mons V., Cachero A., Loinaz-Segurola C., Iñarrairaegui M., et al. Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients. Am. J. Transplant. 2021;21:2876–2884. doi: 10.1111/ajt.16599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.16599</ArticleId><ArticleId IdType="pmc">PMC8251470</ArticleId><ArticleId IdType="pubmed">33835707</ArticleId></ArticleIdList></Reference><Reference><Citation>van Thiel D.H., el-Ashmawy L., Love K., Gavaler J.S., Starzl T.E. Response to hepatitis B vaccination by liver transplant candidates. Dig. Dis. Sci. 1992;37:1245–1249. doi: 10.1007/BF01296567.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01296567</ArticleId><ArticleId IdType="pubmed">1499449</ArticleId></ArticleIdList></Reference><Reference><Citation>Loinaz C., de Juanes J.R., Gonzalez E.M., López A., Lumbreras C., Gómez R., Gonzalez-Pinto I., Jiménez C., Garcia I., Fuertes A. Hepatitis B vaccination results in 140 liver transplant recipients. Hepatogastroenterology. 1997;44:235–238.</Citation><ArticleIdList><ArticleId IdType="pubmed">9058151</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>